Response to ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’’ by Montero et alAlessandro Tomelleri, Lorenzo Dagna, Corrado Campochiaro
2 July 2021
Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’Fernando Montero, Isabel Castrejón, Julia Martínez-Barrio, Juan Carlos Nieto-González, Javier Rivera, José María Álvaro-Gracia, Juan Molina Collada
2 July 2021
Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et alZachary S Wallace, Jeffrey A Sparks, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
23 August 2021
Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Klopfenstein et alRobert BM Landewé, Sofia Ramiro, Rémy L M Mostard
23 June 2021
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’Timothée Klopfenstein, Vincent Gendrin, Thierry Conrozier, Aurélie Gerazime, Marc Puyraveau, Souheil Zayet
23 June 2021
COVID-19 infection after autologous stem cell transplantation for systemic sclerosisJoerg Christoph Henes, Ioana Martac, Wichard Vogel, Claudia Lengerke, Reinhild Klein, Luca Hensen, Ann-Christin Pecher
8 March 2023
Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et alElisa Gremese, Gianfranco Ferraccioli
23 August 2021
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patientsFabio Cacciapaglia, Andreina Manfredi, Gianluca Erre, Matteo Piga, Garifallia Sakellariou, ombretta viapiana, Elisa Gremese, Francesca Romana Spinelli, Fabiola Atzeni, Elena Bartoloni
15 September 2020
Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et alRachael Mary Flood, Richard Conway, Colm Kirby, Diana Gheta, David J Kane, Ronan H Mullan
19 August 2020
Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas
26 April 2021
